Zoetis securities class action faces new scrutiny over over-optimistic claims and regulatory issues

A proposed class action against Zoetis over allegedly misleading claims regarding its companion animal products is progressing, with key deadlines passing as legal firms prepare for court hearings on case validity and lead plaintiff appointment.

The July 27 lead plaintiff deadline in the proposed Zoetis securities class action has now passed, but that date was only about who could seek control of the case, not whether ordinary shareholders may still participate later.

According to the complaint, Zoetis and certain executives presented an over-optimistic picture of the company’s companion animal franchise, particularly around Librela and Simparica Trio. The allegations centre on claims that management overstated product momentum while downplaying regulatory, competitive and safety-related pressures.

Law firms including Bragar Eagel & Squire, Kessler Topaz Meltzer & Check, Levi & Korsinsky, Kirby McInerney and Bernstein Liebhard all flagged the same proposed class period, running from January 14, 2025 to May 6, 2026. That window does not itself guarantee recovery; any eventual payout will depend on class certification, loss-causation findings and trading records.

The Librela allegations stem from an FDA Dear Veterinarian letter in December 2024, which reported adverse events including seizures, paresis and deaths. The complaint argues that this weakened veterinarian confidence more than Zoetis acknowledged. It also says Simparica Trio faced sharper competitive pressure than the market was told.

Zoetis has not been found liable. Next, the court is expected to review any competing lead plaintiff motions, appoint a class representative and then consider whether the case survives a motion to dismiss.